| Literature DB >> 33282606 |
Hani N Mufti1,2,3, Mayar Jarad4, Maryam M Haider5, Lein Azzhary6, Shahad Namnqani4, Imran Husain7, Saad Albugami8, Wael Elamin9.
Abstract
Background Surgical site infection (SSI) after cardiac surgery is a major concern. A limited number of studies have addressed the relationship of preoperative glycemic control on the risk of developing SSI after cardiac surgery. We aim to determine the incidence, microbiological pattern, and impact of preoperative hemoglobin A1C (Hgb A1C) on the development of SSI after cardiac surgery. Methods This is a single-center retrospective chart review that was performed on adult patients undergoing cardiac surgery from January 2017 to December 2018. Results Two hundred and twenty-nine patients underwent 233 procedures. The median age was 60 years; 71% males, 64% were diabetic, and 67% had a Hb A1C above 7% preoperatively. Around 7% of patients developed deep SSI. For patients that developed SSI, 63% had gram-negative bacteria. Hb A1C >7% was not found to be associated with an increased incidence of SSI. Conclusion Our results show that there is no apparent relationship between pre-operative Hgb A1C levels and SSI after cardiac surgery. Although we follow a comprehensive SSI perioperative bundle based on international guidelines that advocates using antibiotics to cover gram-positive organisms, it is interesting that the rate of gram-negative organisms in our patients' cohort is unexpectedly high. We believe that adjusting the perioperative antibiotic regimen based on local microbiological patterns seems to be a reasonable and easily achievable target to decrease the incidence of SSI.Entities:
Keywords: cardiac surgery; glycated hemoglobin (hba1c); microbiological pattern; surgical site infection
Year: 2020 PMID: 33282606 PMCID: PMC7714741 DOI: 10.7759/cureus.11851
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Preoperative characteristics
BMI - body mass index; CKD - chronic kidney disease; IHD - ischemic heart disease; IQR - interquartile range; Hgb A1C - hemoglobin A1C; EURO II SCORE - European system for cardiac preoperative risk evaluation version II, STS: Society of Thoracic Surgeons
| Patient characteristic | n=229 patients |
| Age in years, median (IQR) | 61 (51-67) |
| Male gender, n (%) | 162 (70.7) |
| BMI in kg/m2, median (IQR) | 29 (25.8-32.5) |
| Hypertension, n (%) | 175 (76.4) |
| Diabetes mellitus, n (%) | 150 (65.5) |
| IHD, n (%) | 172 (75.1) |
| Dyslipidemia, n (%) | 185 (80.8) |
| CKD, n (%) | 29 (12.7) |
| Preoperative dialysis, n (%) | 10 (4.4) |
| Smoking, n (%) | |
| Active | 49 (21.4) |
| Ex-smoker | 437 (16.2) |
| Non-smoker | 143 (62.5) |
| Chronic obstructive pulmonary disease, n (%) | 9 (3.9) |
| Preoperative stroke, n (%) | 17 (7.4) |
| Preoperative ejection fraction, n (%) | |
| < 25 % | 4 (1.75) |
| 25-40 % | 34 (14.85) |
| 41-55 % | 108 (47.15) |
| >55% | 71 (31) |
| Unknown | 12 (5.2) |
| Preoperative Hgb A1C, n (%) | |
| ≤ 7 % | 90 (39.3) |
| > 7 % | 108 (47.2) |
| Unknown | 9 (3.9) |
| Preoperative EURO II Score category, n (%) | |
| < 5 % | 203 (88.7) |
| ≥ 5 % | 14 (6.1) |
| Not Applicable | 12 (5.2) |
| Preoperative STS Mortality Score category, n (%) | |
| < 5 % | 207 (90.4) |
| ≥ 5 % | 10 (4.4) |
| Not Applicable | 12 (5.2) |
Intra- and postoperative characteristics
CABG: coronary artery bypass grafts surgery; AVR - aortic valve replacement; MVR - mitral valve replacement; IQR - interquartile range
| Patient characteristic | n=229 patients |
| Procedure status, n (%) | |
| Elective | 172 (75) |
| In-house urgent | 39 (17) |
| Emergency | 13 (5.6) |
| Unknown | 5 (2.2) |
| Procedure, n (%) | |
| CABG | 138 (60.3) |
| AVR | 14 (6.1) |
| MVR | 16 (7) |
| Combined | 33 (14.4) |
| Other | 28 (12.2) |
| Cardiopulmonary bypass time in minutes, median (IQR) | 120.5 (95-165.8) |
| Aortic cross-clamp time in minutes, median (IQR) | 79 (59.3-128.3) |
| Length of stay in the ICU in days, median (IQR) | 5 (4-7) |
| Length of stay in the hospital in days, median (IQR) | 14 (10-20) |
| Postoperative blood transfusion, n (%) | 122 (53.3) |
| Postoperative dialysis, n (%) | 13 (5.7) |
| Postoperative stroke, n (%) | 8 (3.5) |
| Postoperative surgical site infection, n (%) | 67 (29.3) |
| Postoperative mortality, n (%) | 15 (6.6) |
Figure 1SSI requiring surgery
A: Patients categorized based on requiring VAC treatment or not. B: Patients categorized based on the depth of their wounds. C: Patients categorized based on the location of the infection.
Superficial: wounds that affect the skin and subcutaneous tissue but do not reach the underlying facia of the sternum or the muscle in the harvest site.
Deep: wounds that reach down to the facia of the sternum or the muscle in the harvest site.
Osteomyelitis: infection reaching down to or in the boney structure under the wound.
SSI - surgical site infection; VAC - vacuum-assisted closure
Surgical site infection after cardiac surgery
CDC - Center of Disease Control; IQR - interquartile range; SSI - surgical site infection, VAC - vacuum-assisted closure; MRSA - methicillin-resistant Staphylococcus aureus
| Patient characteristic | n=67 patients |
| Time from surgery to infection in days, median (IQR) | 20 (7-32) |
| Surgical site infection CDC category, n (%) | |
| Positive | 21 (31.3) |
| Negative | 46 (68.7) |
| Surgical site infection location, n (%) | |
| Leg (saphenous vein site) | 11 (16.4) |
| Sternum | 54 (80.6) |
| Sternum + leg | 2 (3) |
| Surgical site infection depth, n (%) | |
| Superficial | 50 (75) |
| Deep | 13 (19.4) |
| Osteomyelitis | 3 (4.6) |
| Required VAC, n (%) | 10 (14.9) |
| Wound culture number of organisms, n (%) | |
| One | 39 (58.2) |
| Two | 7 (10.5) |
| Wound culture organisms type by gram stan, n (%) | |
| Gram-negative | 29 (43.3) |
| Gram-positive | 17 (25.4) |
| No organism detected | 17 (25.4) |
| Wound culture organism, n (%) | |
| Staphylococcus aureus | 15 (22.4) |
| Escherichia coli | 7 (10.5) |
| Pseudomonas aeruginosa | 6 (9) |
| Enterobacter | 5 (7.5) |
| Klebsiella pneumoniae | 4 (6) |
| Morganella morganii | 2 (3) |
| MRSA | 2 (3) |
| Serratia marcescens | 5 (7.5) |
| Wound culture second organism, n (%) | |
| Pseudomonas aeruginosa | 4 (6) |
| Klebsiella pneumoniae | 2 (3) |
| Escherichia coli | 1 (1.5) |
| Candida albicans | 1 (1.5) |
| CDC positive organism in wound, n (%) | |
| Staphylococcus aureus | 8 (38.1) |
| Escherichia coli | 2 (9.5) |
| Pseudomonas aeruginosa | 0 (0) |
| Enterobacter | 3 (14.3) |
| Klebsiella pneumoniae | 3 (14.3) |
| Morganella morganii | 2 (9.5) |
| MRSA | 1 (4.8) |
| Serratia marcescens | 2 (9.5) |
| CDC negative organism in wound, n (%) | |
| Staphylococcus aureus | 7 (15.2) |
| Escherichia coli | 5 (10.9) |
| Pseudomonas aeruginosa | 6 (13) |
| Enterobacter | 2 (4.4) |
| Klebsiella pneumoniae | 1 (2.2) |
| Morganella morganii | 0 (0) |
| MRSA | 1 (2.2) |
| Serratia marcescens | 3 (6.5) |
| No organism | 21 (45.6) |
| Postoperative blood culture positive, n (%) | 21 (31) |
| Post-operative SSI requiring surgical intervention, n (%) | 10 (14.9) |
Bivariate analysis showing significant predictors of SSI
SSI - surgical site infection; ICU - intensive care unit; IQR - interquartile range
* Statistically significant with p-value <0.05
| Patient characteristic | Total patients (n=229 patients) | SSI: yes (n=67, 29.3%) | SSI: no (n=167, 70.7%) | P-value |
| Length of stay in the ICU in days, median (IQR) | 5 (4-7) | 6 (4-7.8) | 5 (4-6) | 0.038* |
| Length of stay in the hospital in days, median (IQR) | 14 (10-20) | 17 (12-24) | 13 (10-19) | <0.001* |
Univariate logistic regression for significant predictors of SSI
SSI - surgical site infection; Hgb A1C - hemoglobin A1C; ICU - intensive care unit; OR - odds ratio; CI - confidence interval
* Statistically significant with p-value <0.05
| Patient characteristic | OR (95% CI) | P-value |
| Preoperative Hgb A1C >7% | 1.1 (0.6-2.1) | 0.83 |
| Length of stay in the ICU >8 days | 2.2 (1.1-4.4) | 0.034* |
| Length of stay in the hospital >14 days | 2.1 (1.2-3.9) | 0.013* |
Figure 2Ninety days freedom from SSI after cardiac surgery in adults
SSI - surgical site Infection
Figure 3Significant predictors of development of SSI within 90 days from surgery
A: Gram stain of the primary organism isolated in the wound culture; B: length of stay in the ICU; C: length of stay in the hospital
SSI - surgical site infection; LOS - length of stay; ICU - intensive care unit
Cardiac surgery surgical site infection organism distribution of most recent articles published after 2000
| Author | Year of publication | % of gram-positive organisms | % of gram-negative organisms |
| Ridderstolpe et al. [ | 2001 | 56.5 | Unknown |
| Lepelletier et al. [ | 2013 | 70 | 22 |
| Si et al. [ | 2014 | 53 | 44 |
| Young et al. [ | 2014 | 42.1 | 34.5 |
| Lemaignen et al. [ | 2015 | 49.7 | 39 |
| Figuerola-Tejerina et al. [ | 2016 | 57 | 43 |
| Majid et al. [ | 2020 | 57.5 | 42.5 |
Factors influencing 90 days development of SSI after cardiac surgery
BMI - body mass index; DM - diabetes mellites; IHD - ischemic heart disease; DLP - dyslipidemia; COPD - chronic obstructive pulmonary disease; Hb A1C - hemoglobin A1C; EF - ejection fraction; CABG - coronary artery bypass grafts surgery; CPB - cardio-pulmonary bypass; ICU - intensive care unit; CDC - Center of Disease Control; SSI - surgical site infection; EURO II SCORE - European system for cardiac preoperative risk evaluation version II; STS - Society of Thoracic Surgeons
* Statistically significant with p-value <0.05
| Patient characteristic | Number of patients | Observed | Expected | P-value |
| Age | 0.2 | |||
| ≤60 years | 105 | 26 | 31 | |
| >60 years | 124 | 41 | 36 | |
| BMI | 0.6 | |||
| ≤30 kg/m2 | 133 | 40 | 31 | |
| >30 kg/m2 | 96 | 27 | 36 | |
| Gender | 0.4 | |||
| Male | 162 | 22 | 19.2 | |
| Female | 67 | 45 | 47.8 | |
| DM | 0.4 | |||
| Yes | 150 | 46 | 43 | |
| No | 79 | 21 | 24 | |
| IHD | 0.4 | |||
| Yes | 172 | 53 | 50 | |
| No | 57 | 14 | 17 | |
| DLP | 0.1 | |||
| Yes | 185 | 58 | 53 | |
| No | 44 | 9 | 14 | |
| CKD | 0.3 | |||
| Yes | 29 | 6 | 8.9 | |
| No | 200 | 61 | 58.1 | |
| Smoking, active | 0.2 | |||
| Yes | 49 | 11 | 15.2 | |
| No | 180 | 56 | 51.8 | |
| COPD | 0.7 | |||
| Yes | 9 | 2 | 2.7 | |
| No | 220 | 65 | 64.3 | |
| Hb A1C | 0.3 | |||
| ≤7% | 89 | 23 | 26.9 | |
| >7% | 109 | 37 | 33.1 | |
| EF | 0.1 | |||
| ≤40% | 38 | 15 | 10.4 | |
| >40% | 191 | 52 | 56.6 | |
| Procedure status | 0.1 | |||
| Elective | 172 | 55 | 49.7 | |
| Others | 57 | 12 | 17.3 | |
| Procedure type | 0.8 | |||
| CABG | 138 | 41 | 40 | |
| Others | 91 | 26 | 27 | |
| CPB time | 0.3 | |||
| ≤120 minute | 99 | 33 | 28.7 | |
| >120 minute | 107 | 30 | 34.3 | |
| Cross clamp time | 0.1 | |||
| ≤80 minute | 104 | 37 | 30.5 | |
| >80 minute | 102 | 26 | 32.5 | |
| Length of stay in the ICU | 0.009* | |||
| ≤8 days | 186 | 49 | 56.4 | |
| >8 days | 39 | 17 | 9.61 | |
| Length of stay in the hospital | 0.01* | |||
| ≤14 days | 104 | 22 | 32.5 | |
| >14 days | 39 | 17 | 9.61 | |
| EURO II Score | 0.8 | |||
| ≤ 5% | 203 | 59 | 59.3 | |
| > 5% | 14 | 5 | 4.37 | |
| STS mortality score | 0.5 | |||
| ≤ 5% | 207 | 62 | 60.7 | |
| > 5% | 10 | 2 | 3.3 | |
| CDC SSI Category | 0.9 | |||
| Negative | 46 | 46 | 46.4 | |
| Positive | 21 | 21 | 20.6 | |
| Wound culture | 0.2 | |||
| Negative | 21 | 21 | 17 | |
| Positive | 46 | 46 | 50 | |
| Organism type | 0.04* | |||
| Gram-negative | 29 | 29 | 22.6 | |
| Gram-positive | 17 | 17 | 23.4 | |
| Mortality | 0.2 | |||
| Yes | 15 | 2 | 4.9 |